Four key targets of CS for the treatment of NAFLD, including CASP3, PIK3CA, EGFR, and APP mRNA expression levels were validated using real-time PCR, revealing significantly up-regulated CASP3 (1.003 ± 0.0964 vs. 0.389 ± 0.017, P<0.0001), EGFR (1.003 ± 0.088 vs. 0.705 ± 0.038, P<0.001), and APP (1.004 ± 0.118 vs. 0.816 ± 0.043, P<0.05) gene expressions and down-regulated PIK3CA (1.001 ± 0.056 vs. 1.762 ± 0.374, P<0.01) gene expression in the model group compared with the control group. This evidence concerns the gene CASP3 and metabolic dysfunction-associated steatotic liver disease.